Oncotelic Therapeutics, Inc.
OTC:OTLC
0.04 (USD) • At close November 27, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Oncotelic Therapeutics, Inc. |
Symbool | OTLC |
Munteenheid | USD |
Prijs | 0.037 |
Beurswaarde | 14,731,883 |
Dividendpercentage | 0% |
52-weken bereik | 0.01 - 0.09 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Vuong Trieu Ph.D. |
Website | https://www.oncotelic.com |
An error occurred while fetching data.
Over Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)